An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2017
At a glance
- Drugs BI 754091 (Primary) ; BI 891065 (Primary)
- Indications Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Aug 2017 Planned primary completion date changed from 15 Jan 2018 to 15 Jan 2020.
- 25 Jul 2017 Planned primary completion date changed from 1 Oct 2018 to 15 Jan 2018.
- 25 Jul 2017 Planned initiation date changed from 14 Jul 2017 to 14 Aug 2017.